Drug safety evaluation of apremilast for treating psoriatic arthritis

Expert Opinion on Drug Safety

Volumn 14, Issue 6, 2015, Pages 979-985

  Busa, Swapna ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apremilast; Efficacy; PDE4 inhibitor; Psoriatic arthritis; Safety

Indexed keywords

APREMILAST; PLACEBO; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ABNORMAL LABORATORY RESULT; AREA UNDER THE CURVE; ARTICLE; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEOPLASM; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG MONITORING; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 84929574396     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1031743     Document Type: Article

References (22)

1. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica 2011;41(12):1063-75
2. Otezla (apremilast) [prescribing information]. Celgene Corporation; Summit, NJ: 2014
3. Wu A, Rohane P, Ng J, et al. Safety/tolerability and pharmacokinetics of multiple oral doses of apremilast in healthy male subjects [abstract]. Clin Pharmacol Ther 2012;91:S26
4. Cada DJ, Ingram K, Baker DE. Apremilast. Hosp Pharm 2014;49(8):752-62
5. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83(12):1583-90
6. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates antiinflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842-55
7. Straub RH, Bijlsma JW, Masi A, et al. Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases-the 10-year update. Semin Arthritis Rheum 2013;43(3):392-404
8. Cutolo M, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three Phase III, randomized, controlled trials. Arthritis Rheum 2013;65:S135-6
9. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a Phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 2015. [Epub ahead of print]
10. Cutolo M, Myerson GE, Fleischmann RM, et al. Long-Term (52-Week) results of a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract]. Arthritis Rheum 2013;65(Suppl 10):815
11. Edwards CJ, Blanco FJ, Crowley J, et al. Long-term 52-week results of PALACE 3, a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement [abstract 212]. Rheumatology 2014;53(Suppl 1):i138
12. Schett G, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in physical function in patients with psoriatic arthritis: results from three Phase III, randomized, controlled trials. Arthritis Rheum 2013;65:S143
13. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a Phase III, randomized, controlled trial. Arthritis Rheum 2012;64(12):4172-3
14. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 Phase III, randomized, controlled trials [abstract 548]. Arthritis Rheum 2014;66(11 Suppl):S239 .. Pooled results of PALACE trials.
15. Apremilast, an oral phosphodiesterase 4 inhibitor, and the impact of baseline weight and BMI on ACR20 and HAQ-DI response: pooled results from 3 Phase III, randomized, controlled trials [abstract 1561]. Arthritis Rheum 2014;66(11 Suppl):S689
16. Mease PJ, Kavanaugh A, Gladman D, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three Phase III, randomized, controlled trials [abstract SAT0408]. Ann Rheum Dis 2014;73(Suppl2):742 .. Pooled safety analysis of PALACE trials
17. Mease PJ. Apremilast: phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther 2014;1:1-20
18. Mease PJ, Kavanaugh A, Adebajo A, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three Phase III, randomized, controlled trials [abstract 348]. Arthritis Rheum 2013;65(10 Suppl):S151 . Pooled laboratory abnormalities of PALACE trials.
19. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a Phase III, randomized, controlled trial and open-label extension (PALACE 1) [abstract 1564]. Arthritis Rheum 2014;66(11 Suppl):S690
20. Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 2014;15(1):85-96
21. Change in weight from baseline with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 Phase III, randomized, controlled trials [abstract 1579]. Arthritis Rheum 2014;66(11 Suppl):S698
22. Wouters EF, Teichmann P, Brose M, et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:A4473